Research and Markets, the largest resource for market research information in world providing essential market research reports, industry research, industry analysis, forecasts, market studies, company profiles and country reports.
Welcome - Home - Register - Login - Help/FAQ - 0 items View Basket
Worlds Largest Market Research Resource - 722206 Live Reports
Search Research and Markets
  Search
Enter keywords, a title or
a report id number below.





Advanced   
Company search
Register for free email updates of market research
Currency
  Select a currency for use throughout the site



Viewing report

Order by Fax
Printer Friendly
PDF Brochure
Send to Friend
Enquire before Buying
| More
Hard CopyAdd to Basket
Electronic (PDF)Add to Basket
EnterprisewideAdd to Basket



Stakeholder Opinions: Non-Hodgkins Lymphoma - Is there room to emulate Rituxans success?
Datamonitor, Dec 2007, Pages: 174


  Description  
  Table of Contents  
  Companies Mentioned  
    
    
   
 Enquire before Buying  
 Send to a Friend  

Non-Hodgkins lymphoma (NHL) is the most common hematological malignancy and is comprised of around 30 different disease subtypes. Each of these present with a distinct set histological, genetic and clinical characteristics.

Treatment options in NHL include chemotherapy, targeted therapies, stem cell transplantation and radiotherapy.

Scope

- NHL background and epidemiology, including forecast incidence of the major subtypes in the seven major markets

- Treatment of NHL by subtype and line of therapy, including major treatment controversies and areas of unmet need

- Examination of pipeline activity including profiles of late-phase pipeline drugs

- Stakeholder opinions based on qualitative interviews with opinion leaders from the US and Europe

Highlights of this title

Rituxan-based regimens constitute the mainstay of first-line treatment options in several NHL subtypes. Uptake of Rituxan in the maintenance setting for follicular lymphoma (FL) has allowed the drug to achieve further market penetration.

There is a lack of consensus over the treatment of relapsed and refractory disease in most NHL subtypes. Refractory patients are poorly served by currently available treatment options. Other unmet needs include detection of patients with aggressive lymphoma at high risk of relapse and an efficacious maintenance therapy for these patients.

The NHL late-phase pipeline is relatively active, with 10 Phase IIII drugs and 46 Phase II drugs. Monoclonal antibodies are among those agents that continue to demonstrate promising signs of clinical and commercial potential. However, Rituxans status as market leader is unlikely to be challenged within the next 510 years.

Key reasons to purchase this title

- Understand current epidemiological trends in non-Hodgkins lymphoma and ongoing treatment options

- Identify limitations of therapy currently available to non-Hodgkins lymphoma patients and the potential of future therapy

- Identify the key products in late-phase development for NHL. Consider, assess and react to opportunities and risks influencing their future potential



Customers who bought this item also bought

Prospects for the Phase III Bapineuzumab Trial

MabThera in NHL Maintenance Therapy Phase III Results Call - Roche Holding AG - Earnings Transcript

Innovations and Trends in Clinical Trials - Microdosing (Phase 0 Trials), Adaptive Trials, Phase IV Trials and the Role of Information Technology

Cell Therapy Clinical Trial Analysis

Stakeholder Opinions: Non-Hodgkins Lymphoma - Immunotherapy Stimulates the Market

Pipeline Insight: Hematological Malignancies - Pursuit For The Next Blockbuster Intensifies

CR011-vcMMAE Phase II Clinical Trial Results Call - CuraGen Corp., - Earnings Transcript

TNFerade Phase III Clinical Trial Results Call - GenVec, Inc., - Earnings Transcript

Oncology Devices Clinical Trial Analysis

Acetavance(TM) Phase III Clinical Trial Results Call - Cadence Pharmaceuticals, Inc. - Earnings Transcript

Elagolix PETAL Phase II Clinical Trial Results Call - - Earnings Transcript

Hemostats Clinical Trial Analysis



Top of page


   All rights reserved. � Copyright 2009 Research and Markets
   Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster


Research and Markets RSS Feeds